Phaseline

Companies › Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Respiratory; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ensifentrine (MK-5884)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Pulmonary Disease, Chronic Obstructive, COPD; Non-cystic Fibrosis BronchiectasisMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05270525Ensifentrine (MK-5884)Phase 2Pulmonary Disease, Chronic Obstructive, COPDRespiratoryMar 2027
NCT06559150Ensifentrine (MK-5884)Phase 2Non-cystic Fibrosis BronchiectasisRespiratorySep 2027

Targets

PDE4A (1) PDE4D (1) PDE4B (1) PDE4C (1) PDE3A (1)

Companies with the same targets

MediciNova Merck & Co. (MSD) Amgen Ganzhou Hemay Pharmaceutical Arcutis Biotherapeutics Integrative Skin Science and Research Shionogi Tetra Discovery Partners Tenax Therapeutics

Companies built like this

Aimmune Nestlé Health Science US R&D Vicore Pharma SpliSense ReCode Therapeutics Anagram Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.